Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZR18 injection bioequivalence study in healthy males
NCT07355738Phase 1Recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Jan 2026
- Primary completion
- May 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bofanglutide in obesity and type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoints: Maximum Concentration, Area Under the Concentration-Time Curve During a Dosing Interval and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
bofanglutide
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07355738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07355738.